Erick K. Rowinsky

Erick K. Rowinsky's AcademicInfluence.com Rankings

Erick K. Rowinsky

Medical

#1470

World Rank

#1810

Historical Rank

Oncology

#61

World Rank

#65

Historical Rank

Pharmacology

#124

World Rank

#157

Historical Rank

medical Degrees

Erick K. Rowinsky

Philosophy

#4595

World Rank

#7173

Historical Rank

Logic

#2011

World Rank

#2904

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Erick K. Rowinsky Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Erick K. Rowinsky's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010) (1824)
Drug therapy : paclitaxel (Taxol) (1995) (1275)
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. (2004) (1090)
Taxol: a novel investigational antimicrotubule agent. (1990) (1057)
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. (2001) (1008)
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. (1989) (885)
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (2006) (843)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (2002) (773)
Clinical toxicities encountered with paclitaxel (Taxol). (1993) (694)
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. (1997) (687)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). (2003) (650)
The current status of camptothecin analogues as antitumor agents. (1993) (623)
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy (2000) (618)
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. (2000) (612)
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. (1999) (535)
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. (2006) (526)
Paclitaxel (taxol) (1995) (513)
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. (2010) (489)
Taxol: the first of the taxanes, an important new class of antitumor agents. (1992) (431)
Sequences of taxol and cisplatin: a phase I and pharmacologic study. (1991) (427)
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. (1988) (393)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules (2003) (362)
Cardiac disturbances during the administration of taxol. (1991) (359)
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. (1992) (358)
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies (1994) (352)
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. (2004) (322)
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. (1991) (318)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors (2009) (314)
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. (1992) (286)
Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. (1995) (275)
Raf: a strategic target for therapeutic development against cancer. (2005) (273)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. (2008) (270)
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. (2002) (267)
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (2011) (257)
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) (251)
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. (1992) (229)
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. (1994) (224)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. (2004) (224)
Neurotoxicity of Taxol. (1993) (222)
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. (1996) (209)
Phase I and pharmacodynamic study of taxol in refractory acute leukemias. (1989) (207)
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer (2006) (202)
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. (2005) (199)
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. (1999) (195)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. (1993) (194)
The ErbB receptor family: a therapeutic target for cancer. (2002) (192)
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. (1995) (190)
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. (2003) (187)
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. (2014) (187)
Phase I trial of taxol in patients with advanced cancer. (1987) (184)
A reassessment of cardiac toxicity associated with Taxol. (1993) (182)
The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer (2003) (177)
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. (1996) (175)
Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. (1997) (167)
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor (2007) (163)
A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer (2005) (161)
Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. (2001) (159)
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. (2007) (157)
Targeting the molecular target of rapamycin (mTOR) (2004) (154)
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. (2011) (152)
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. (2003) (152)
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. (1996) (151)
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. (1996) (143)
Mammalian target of rapamycin: a new molecular target for breast cancer. (2003) (143)
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies (2009) (140)
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. (1998) (139)
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. (2006) (134)
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. (2003) (133)
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. (1992) (131)
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. (1994) (125)
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. (1999) (121)
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. (2002) (118)
Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab (2008) (118)
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. (2003) (117)
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. (2002) (117)
Phase I and pharmacologic study of topotecan in patients with impaired renal function. (1996) (115)
Successful re-treatment with taxol after major hypersensitivity reactions. (1993) (112)
Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors (2008) (110)
Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells (2010) (109)
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. (1990) (107)
Development of polyploidization in taxol-resistant human leukemia cells in vitro. (1990) (107)
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. (2001) (100)
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer (2011) (100)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. (2006) (100)
Vascular endothelial growth factor receptor‐1 in human cancer (2010) (99)
The clinical pharmacology of paclitaxel (Taxol). (1993) (99)
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma (2000) (98)
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. (2000) (97)
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. (2000) (95)
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. (2002) (92)
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. (2001) (92)
Signal events: Cell signal transduction and its inhibition in cancer. (2003) (88)
Hepatic metabolism and biliary excretion of Taxol in rats and humans. (1993) (84)
Taxol: twenty years later, the story unfolds. (1991) (83)
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. (1996) (82)
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. (2000) (82)
Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy (2007) (81)
Taxol: pharmacology, metabolism and clinical implications. (1993) (81)
Paclitaxel pharmacology and other tumor types. (1997) (79)
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors (2002) (79)
A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies (2010) (78)
Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule (2004) (78)
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer (2004) (75)
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. (2000) (73)
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. (2010) (72)
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. (1999) (71)
Novel agents that target tublin and related elements. (2006) (70)
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. (2008) (70)
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. (1999) (69)
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. (1999) (69)
An overview of experience with TAXOL (paclitaxel) in the U.S.A. (1993) (67)
Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α (2010) (67)
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas (2004) (66)
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. (1997) (66)
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. (1997) (64)
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. (1999) (64)
Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. (1994) (64)
Population pharmacokinetic model for topotecan derived from phase I clinical trials. (2000) (64)
Progress in the management of gynecologic cancer: consensus summary statement. (2003) (63)
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. (2007) (62)
A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer (2008) (62)
A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies. (2004) (61)
Therapeutics targeting signal transduction for patients with colorectal carcinoma. (2002) (61)
Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. (1999) (60)
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma (2012) (59)
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent (2015) (59)
A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties (2004) (58)
The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. (1996) (58)
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors (2006) (56)
Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies (2005) (54)
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. (1996) (54)
Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. (1994) (54)
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. (1996) (54)
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. (1998) (54)
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. (1998) (53)
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. (2000) (53)
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. (2003) (53)
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. (1997) (53)
Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer (2007) (51)
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. (2006) (51)
Clinical pharmacology of Taxol. (1993) (51)
Update on the Antitumor Activity of Paclitaxel in Clinical Trials (1994) (50)
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993. (1994) (50)
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial (2007) (50)
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. (1998) (49)
Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas (2005) (48)
Paclitaxel in cancer treatment (1995) (48)
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. (1993) (48)
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. (1996) (48)
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas (2007) (46)
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma (2007) (46)
Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients (2010) (46)
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial (2011) (46)
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea (1998) (46)
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay (1999) (46)
Novel Anticancer Agents in Clinical Development (2003) (46)
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. (2001) (45)
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. (2000) (45)
Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies (2004) (45)
Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. (2006) (44)
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies (2004) (44)
SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia (2014) (43)
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key (2003) (43)
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine (2005) (43)
The taxanes: dosing and scheduling considerations. (1997) (43)
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma (2020) (42)
A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. (2001) (41)
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer (2010) (41)
Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer. (1986) (41)
The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study (2004) (41)
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. (2018) (41)
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. (2002) (41)
UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. (1999) (41)
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. (2001) (40)
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. (1990) (40)
Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies (2011) (39)
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. (1995) (39)
Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer (2011) (38)
Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells. (1989) (38)
Review of phase I clinical studies with topotecan. (1997) (38)
Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma (2004) (37)
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. (1995) (36)
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390). (1990) (36)
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. (2000) (36)
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data (2004) (35)
Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer (2006) (35)
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study. (1987) (34)
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. (1998) (34)
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. (2003) (34)
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. (1998) (34)
Handbook of Anticancer Drug Development (2003) (33)
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. (2003) (32)
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. (1998) (32)
Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells (2015) (32)
Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies (2005) (31)
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. (2002) (31)
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining (2011) (31)
Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies (2009) (30)
Topotecan in combination chemotherapy. (1997) (30)
A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients (2005) (30)
Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics. (1989) (30)
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC) (2001) (30)
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies (2009) (29)
Spontaneous pneumothorax following thoracic irradiation. (1985) (29)
P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy (2003) (29)
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. (1997) (28)
Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer? (1995) (28)
A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms (2004) (28)
Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. (2001) (28)
A phase II trial of topotecan in patients with previously untreated pancreatic cancer (1996) (28)
Patient Care Issues: The Management of Paclitaxel-Related Toxicities (1994) (28)
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? (2002) (27)
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. (2000) (27)
Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. (2013) (27)
Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors (2006) (26)
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. (2000) (26)
Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. (2004) (26)
Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. (2004) (26)
Pharmacokinetic profiles of doxorubicin in combination with taxanes. (2001) (25)
Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors (2002) (24)
Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy. (1991) (24)
Camptothecin analogues: studies from The Johns Hopkins Oncology Center (2004) (24)
Novel radiation sensitizers targeting tissue hypoxia. (1999) (23)
Dose-intense paclitaxel: deja vu all over again? (2003) (23)
Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. (1999) (22)
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. (1997) (22)
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers. (2011) (22)
Clinical experience with monoclonal antibodies to epidermal growth factor receptor (2005) (22)
Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors (2010) (21)
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. (1998) (20)
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer (2012) (19)
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML) (2015) (19)
A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) (2005) (19)
Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors (2008) (18)
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units (2004) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Regulation of c-Raf-1: therapeutic implications. (2003) (18)
Massive adrenal hemorrhage secondary to metastatic lung carcinoma. (1986) (18)
Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. (2004) (18)
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells. (1999) (17)
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days (2004) (17)
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. (1992) (17)
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer. (1994) (17)
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. (1998) (16)
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion. (1998) (16)
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML (2012) (16)
Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. (2004) (16)
Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes". (2002) (16)
Curtailing the High Rate of Late-Stage Attrition of Investigational Therapeutics Against Unprecedented Targets in Patients with Lung and Other Malignancies (2004) (16)
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. (1990) (15)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor (2004) (15)
Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. (2004) (15)
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer (2004) (15)
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"? (2002) (15)
Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel (2007) (15)
Alternative dosing schedules for irinotecan. (1998) (15)
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. (1995) (15)
Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity. (1988) (14)
Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a (1996) (14)
On pushing the outer edge of the outer edge of paclitaxel's dosing envelope. (1999) (14)
IMC-A 12 , a Human IgG 1 Monoclonal Antibody to the Insulin-Like Growth Factor IReceptor (2007) (14)
Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. (2004) (14)
The new generation of targeted therapies for breast cancer. (2003) (14)
Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies (2008) (14)
Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue (2006) (14)
Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma. (1999) (14)
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. (2003) (13)
A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum (2004) (13)
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC) (2012) (13)
Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers (2007) (13)
Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target For SL-101 In Acute Myeloid Leukemia With FLT3-ITD Mutations (2013) (13)
The effects of food and divided dosing on the bioavailability of oral vinorelbine (1996) (13)
Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. (1995) (13)
A Risk-Benefit Assessment of Irinotecan in Solid Tumours (1998) (13)
Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model (2013) (12)
7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697) (2009) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies. (2003) (12)
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. (2001) (12)
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors. (2004) (12)
The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents (2012) (12)
Murine and human in vivo penclomedine metabolism. (1996) (12)
Microtubule-Targeting Natural Products (2003) (11)
166 A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors (2004) (11)
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors. (1997) (11)
Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer (2001) (11)
Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial (2004) (11)
Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer (2008) (10)
Intraperitoneal administration of Taxol in the management of ovarian cancer. (1993) (10)
Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay. (1999) (10)
A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors (2009) (10)
A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies (2007) (10)
EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) (2007) (10)
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. (1998) (10)
The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases (2000) (9)
Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10 (2010) (9)
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (2013) (9)
Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies (2012) (9)
A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis (2007) (9)
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. (2004) (9)
Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors. (2004) (9)
Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies. (2018) (9)
The distribution of systemically administered (1995) (9)
Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids (1991) (9)
Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors (2005) (9)
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies. (2003) (9)
Tissue and tumor distribution of C-penclomedine in rats. (1996) (8)
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. (2000) (8)
Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission (2014) (8)
Extended temozolomine (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AGAT) (2001) (8)
Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR{alpha} in patients with advanced solid malignancies (2008) (8)
The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum (2003) (8)
648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer (2006) (8)
Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial. (2004) (7)
A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer (2003) (7)
A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers (2005) (7)
A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC) (2008) (7)
Phase I and pharmacokinetic study of hepsulfam (NSC 329680). (1991) (7)
Nifedipine and oncologic Raynaud phenomenon. (1988) (7)
Erosion of the principal investigator role in a climate of industry dominance. (2005) (7)
Phase I trial of adriamycin (A) + taxol (T) in metastatic breast cancer (MBC) (1993) (7)
Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. (2006) (7)
Anti-leukemia efficacy and mechanisms of action of SL-101, a novel anti-CD123 antibody-conjugate in acute myeloid leukemia (2014) (6)
Absorption, Metabolism, and Excretion of C-Temozolomide following Oral Administration to Patients with Advanced Cancer (1999) (6)
Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside (2000) (6)
369 A phase II, pharmacokinetic (PK) and biological correlative study of OSI-774 (Tarceva) in patients with advanced renal cell carcinoma, with FDG-PET imaging: evidence of durable stable disease and antitumor activity (2004) (6)
Hexamethylene bisacetamide-induced cutaneous vasculitis. (1987) (6)
Duration of Mucositis and Dysphagia following Radiotherapy (+ Cetuximab) for Locoregionally Advanced Head and Neck Cancer (2007) (6)
Association of a germ-line variant in the K-ras 3' untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. (2009) (6)
411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials (2004) (6)
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (6)
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. (1999) (6)
The Vinca Alkaloids (2003) (6)
mTOR Inhibition for Cancer Therapy: Past, Present and Future (2016) (5)
409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study (2004) (5)
EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. (2006) (5)
Early Clinical Experience with Farnesyl Protein Transferase Inhibitors (2001) (5)
A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report. (2020) (5)
Phase I, pharmacokinetic (PK) study of synthadotin (SYN-D; ILX651), a next generation antitubulin, administered iv weekly x 3 weeks every 4 weeks (wx3q4w). (2004) (5)
Abstract #2774: The fully human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin+gemcitabine in human non-small cell lung cancer models (2009) (5)
Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331 (1999) (5)
SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Possesses Preclinical Cytotoxic Activity Against Chronic Eosinophilic Leukemia (2013) (5)
A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti- epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first- line therapy (2008) (5)
Docetaxel: assessing a range of activity. (2001) (4)
Randomized phase II trial of pegylated liposomal doxorubicin (PLD) with or without anti-platelet-derived growth factor receptor-alpha (PDGFR-alpha) monoclonal antibody IMC-3G3 in platinum-refractory/resistant advanced ovarian cancer. (2010) (4)
Pharmacokinetic (PK) and pharmacodynamic analysis of aspirin administered with multi-targeted antifolate (ALIMTA) (2001) (4)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor. (2004) (4)
Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases. (2017) (4)
Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds (1996) (4)
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia (1995) (4)
Clinical and pharmacologic reappraisal of dichloromethotrexate. (1988) (4)
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPYAGENTS (1997) (4)
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer. (2004) (4)
Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy (2004) (4)
4 Metabolism and pharmacology of taxoids (1995) (4)
55 A phase I study of SB-715992, a novel kinesin spindle protein (KSP) inhibitor: pharmacokinetic (PK)/pharmacodynamic (PD) modeling of absolute neutrophil counts (ANC) (2004) (3)
Phase I and pharmacokinetic (PK) study of troxacitabine (b-L-dioxolan-cytidine;BCH-4556) on a daily × 5 day every 4-week schedule (1999) (3)
Safety and pharmacokinetics (PK) of T138067 (T67) administered as a weekly 3-hour infusion in subjects with hepatocellular carcinoma (HCC) in a phase 1 study. (2004) (3)
Preclinical and Clinical Development of Exatecan (DX-951f) (2005) (3)
Human epidermal growth factor receptor-2 (HER2) Ile655Val single nucleotide polymorphism (SNP) is associated with gender-specific outcome in patients with metastatic colorectal cancer (mCRC) treated with cetuximab in a phase II study (IMCL-0144). (2011) (3)
Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. (2006) (3)
30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors (2004) (3)
511 POSTER Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFRa) in patients with advanced solid malignancies (2008) (3)
IT-02INITIATION OF CLINICAL STUDIES WITH SL-701, A SYNTHETIC MULTI-PEPTIDE VACCINE WITH ENHANCED IMMUNOSTIMULATORY PROPERTIES TARGETING MULTIPLE GLIOMA-ASSOCIATED ANTIGENS, IN ADULTS WITH FIRST RECURRENCE OF GLIOBLASTOMA (2014) (3)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. (2004) (3)
Crossing the cancer cell membrane to improve clinical outcomes. (2003) (3)
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors (2004) (3)
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor (2005) (3)
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2013) (3)
A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. (2004) (2)
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies (2009) (2)
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia (2014) (2)
Pilot Trial of Alternating Paclitaxel and Doxorubicin in Advanced Breast Cancer (1997) (2)
Abstract PO-018: Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus (2021) (2)
Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel (2004) (2)
HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. (2021) (2)
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies (2004) (2)
A remedy for biomarker addiction: back to rational anticancer drug development (2007) (2)
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma. (1997) (2)
599 Phase I and pharmacokinetic (PK) study of OSI-7904L in combination with Cisplatin (CDDP) in patients with advanced solid tumors (2004) (2)
Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors (2007) (2)
A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction. (2004) (2)
Acute retinal toxicity from the novel anti-tumor agent, Irofulven (2004) (2)
Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine (2001) (2)
Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody (IMC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC). (2010) (1)
SL-501, a Next-Generation Targeted Therapy Directed to the IL-3 Receptor (IL-3R), Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma (2014) (1)
Sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy. (1987) (1)
Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer (2002) (1)
Taxol (T): An active new drug in ovarian epithelial cancer (OVCA) (1989) (1)
Phase 1 and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system (HDDS) for paclitaxel. (2004) (1)
A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism (2015) (1)
406 POSTER IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study (2008) (1)
SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma. (2012) (1)
Plasma 2 '-deoxyuridine (dUrd) as a surrogate marker of thymidylate synthase (TS) inhibition in patients in phase I clinical trials of the TS inhibitor ZD9331 (1998) (1)
Targeting the target of rapamycin (TOR): looking to mother nature (2011) (1)
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study (1989) (1)
140 A two-stage phase II study of the matrix metalloproteinase inhibitor (MMPI) Col-3 in patients with advanced soft tissue sarcoma (ASTS) — report of stage I data (2004) (1)
41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B (2008) (1)
Erratum: A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes (Investigational New Drugs DOI: 10.1007/s10637-006-9031-6) (2007) (1)
in blastic plasmacytoid dendritic cell neoplasm patients Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, (2014) (1)
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor on Cancer Stem Cells and Tumor Bulk, Has Broad Clinical Activity and Tolerability as a Single Agent in Patients with Advanced Hematological Malignancies (2013) (1)
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease. (2014) (1)
Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies (2018) (1)
550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer (2004) (1)
Agents Targeting Microtubules and Mitotic Processes (2017) (1)
Docetaxel in combination with fluorouracil: study design and preliminary results. (1997) (1)
623 Trial in progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies (2022) (1)
Microtubule changes and cytotoxicity produced by taxol in human ovarian cell lines (1987) (1)
A phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in combination with weekly paclitaxel in patients (pts) with advanced solid cancers. (2004) (1)
Clinical and preclinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk of hematologic malignancies, against blastic plasmacytoid dendritic cell neoplasm (BPDCN). (2013) (1)
SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity (2015) (1)
Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC). (2009) (1)
Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors. (2020) (1)
Analysis of dose proportionality testing methods in phase I clinical trials of anticancer agents (2005) (1)
387 A phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (2004) (1)
A widening prospect: Imatinib and novel applications of targeted therapy. (2004) (1)
Abstract CT146: RGX-104, a first-in-class immunotherapy targeting the liver-X receptor (LXR): Initial results from the phase 1b RGX-104 plus docetaxel combination dose escalation cohorts (2020) (1)
Abstract P2-06-07: StemScreen®, an innovative platform technology for the identification of novel cancer stem cell-directed compounds (2015) (0)
607 POSTER Impressive anti-tumor activity of combined erbB1 and erbB2 blockade: a phase I and pharmacokinetics (PK) study of OSl-774 (Erlotinib; E) and Trastuzumab (T) in combination with weekly Paclitaxel (P) in patients (pts) with advanced solid tumors (2006) (0)
Phase I study of lapatinib (GW572016) in combination with letrozole in cancer patients (2005) (0)
Phase I a nd P harmacologic S tudy o f P N401 a nd F luorouracil in P atients W ith A dvanced S olid M alignancies (2000) (0)
Targeting mTOR: A Little Bit of History and a Large Future (2016) (0)
Cixutumumab (2010) (0)
Abstract 1329: Personalizing gastrointestinal cancer treatment by the utilization of TumorGraft™ technology (2012) (0)
444 A phase I/II study of oblimersen sodium in combination with oxaliplatin, 5-FU and leucovorin (FOLFOX4 regimen) in patients with advanced colorectal cancer (2004) (0)
A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 0771 (2000) (0)
APhase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer (2008) (0)
Abstract 4189: Utilization of Champions Tumorgraft™ models to identify putative biomarkers and signatures of response (2011) (0)
Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1 (2006) (0)
1. Bogner L, Hartmann M, Rickhney M and Zdenek M. Application of an inverse kernel concept to Monte Carlo based IMRT. Med Phys 2006; 33, Nr. 12: 4749-4757 (ISSN 0094-2405 - IF 2,305). (2006) (0)
APhase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies (2007) (0)
Metastatic Cancer Supplementation in Patients with Locally Advanced or High-Dose Folic Acid Supplementation or Multivitamin Phase I and Pharmacokinetic Study of Pemetrexed with (2007) (0)
Novel Compounds Targeting Microtubules and Related Organelles (2003) (0)
514 Pharmacokinetic study of the distribution, metabolism and excretion of non-radiolabeled DX 8951f following repeated intravenous administration to patients with solid tumors (2004) (0)
A P hase I a nd P harmacokinetic S tudy o f P egylated Camptothecin a s a 1 -Hour I nfusion E very 3 W eeks i n P atients With A dvanced S olid M alignancies (2003) (0)
Innovative Rational-Derived, Target-Based and Cytotoxic Therapies for Breast Cancer and Other Malignancies (2006) (0)
Phase I and Pharmacokinetic Study of XRP 6258 ( RPR 116258 A ) , a NovelTaxane , Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced SolidTumors (2009) (0)
PATIENTS AND METHODS (1982) (0)
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2009) (0)
A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors (2007) (0)
Abstract 4507: SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the growth of tyrosine kinase inhibitor-resistant CML cells (2014) (0)
433 Anti-cancer activity of onconase, a cytotoxic amphibian ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models (2010) (0)
Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144). (2010) (0)
Clinical Status and Optimal Use of Topotecan (2017) (0)
New antimitotic agents. (2004) (0)
Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies (1999) (0)
Population P harmacokinetic M odel f or T opotecan D erived From P hase I C linical T rials (2000) (0)
Pharmacokinetics of synthadotin (ILX651), a novel tubulin polymerization inhibitor, in patients with solid tumors. (2004) (0)
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis (2014) (0)
Commentary (Patnaik/Rowinsky)—Epidermal Growth Factor Receptor Inhibitors for the Treatment of Colorectal Cancer: A Promise Fulfilled? (2004) (0)
A Phase I and Pharmacokinetic Study of Squalamine , an Aminosterol Angiogenesis Inhibitor 1 (2003) (0)
Onconase, a cytotoxic ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models. (2011) (0)
Phase I a nd P harmacologic S tudy o f O SI-774, a n Epidermal G rowth F actor R eceptor T yrosine K inase Inhibitor, i n P atients W ith A dvanced S olid M alignancies (2001) (0)
Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patientswith Advanced SolidTumors (2005) (0)
A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification (2004) (0)
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies. (1999) (0)
Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer: Future Drug Development (2002) (0)
554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies (2008) (0)
A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1 (2001) (0)
Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1 (2006) (0)
A pharmacokinetic (PK) dose escalation study of DX-8951f (DX) in adult cancer patients with hepatic dysfunction: A comparison of the NCI hepatic dysfunction criteria and the Child-Pugh classification. (2004) (0)
Abstract LB-133: Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a first-in-class Liver-X-Receptor (LXR) agonist, and clinical outcomes in patients with advanced solid tumors (2020) (0)
Abstract 5252: Utilization of TumorGraft technology for personalized breast cancer treatment (2012) (0)
Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies (2023) (0)
Instructions for Authors (2004) (0)
Cantuzumab M ertansine, a M aytansinoid I mmunoconjugate Directed t o t he C anAg A ntigen: A P hase I , P harmacokinetic, and B iologic C orrelative S tudy (2003) (0)
A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors 1 (1999) (0)
467 INVITED The targeted oncology platform at ImClone Systems: novel receptor blocking antibody therapeutics and approaches (2008) (0)
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices. (1995) (0)
Acknowledgement of Reviewers 2017 (2018) (0)
Note from the Reviews Section Editorial Board (2005) (0)
469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies (2021) (0)
Phase I a nd P harmacokinetic S tudy o f L U79553, a D NA Intercalating B isnaphthalimide , i n P atients W ith S olid Malignancies (2001) (0)
Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination (1991) (0)
Microtubules as Strategic Targets Against Cancer (2003) (0)
Phase I a nd P harmacokinetic S tudy o f t he O ral Fluoropyrimidine C apecitabine i n C ombination W ith Paclitaxel i n P atients W ith A dvanced S olid M alignancies (1999) (0)
Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors (2006) (0)
Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance. (2013) (0)
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomes (2007) (0)
Docetaxel in Combination With Flourouracil: Study Design and Preliminary Results (1997) (0)
367 Emerging pharmacokinetic (PK)-pharmacodynamic (PD) profile of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (2004) (0)
Preclinical activity of SL-801, a reversible inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) in solid and hematologic cancers. (2015) (0)
Commentary (Rowinsky): New Anticancer Agents in Clinical Development (1995) (0)
mline Polymorphisms in Genes Involved in the IGF 1 hway Predict Efficacy of Cetuximab in Wild-type R S mCRC Patients (2010) (0)
Pharmacokinetic Study ofTemsirolimus ( CCI-779 ) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer (2006) (0)
Randomized P hase I T rial o f R ecombinant H uman Keratinocyte G rowth F actor P lus C hemotherapy: P otential R ole as M ucosal P rotectant (2003) (0)
529 Nonlinear pharmacokinetic modeling of XAA296 administered to patients with advanced solid tumors once every 3 weeks (q3w) intravenously (IV) in a phase I clinical trial (2004) (0)
Towards personalized medicine: Evaluation of blood and tissue biomarkers for drug sensitivity in a newly established human xenograft model (2006) (0)
Cancer Therapy: Clinical Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies (2009) (0)
25 Pharmaceutical industry, investigators and institutions: partners or tools? Practical issues in clinical cancer drug development. Erosion of the principal investigator in a climate of industry dominance (2004) (0)
Pathophysiological Mechanism for Rest enosis Following Coronary Antioplasty : Possible Preventive Alternatives (2017) (0)
Fully Human IgG 1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies (2010) (0)
Phase I Study of Taxol Using a 5-Day Intermittent Schedule (2017) (0)
Tubulin-Targeting Drugs (2001) (0)
Towards personalized medicine: Establishment and in vivo characterization of a low passage tumor xenograft tumor predictive of clinical response (2007) (0)
A Phase I and Pharmacokinetic Study of SAM 486 A , a Novel Polyamine Biosynthesis Inhibitor , Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies 1 (2002) (0)
270 Human primary colon tumorgraft models possess similar clinical response characteristics (2010) (0)
Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies (2006) (0)
406 POSTER Establishment and in vivo evaluation of two human sarcoma xenograft models: results of tumor growth and chemotherapy sensitivity in models of mesenchymal chondrosarcoma (MCS) and leiomyosarcoma (LMS) (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Erick K. Rowinsky?

Erick K. Rowinsky is affiliated with the following schools:

Erick K. Rowinsky's Academic­Influence.com Rankings

Why Is Erick K. Rowinsky Influential?

Erick K. Rowinsky's Published Works

Published Works

What Schools Are Affiliated With Erick K. Rowinsky?

Erick K. Rowinsky's AcademicInfluence.com Rankings